Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-I (IGF-I) and insulin interact with related receptors to lower plasma glucose and to exert mitogenic effects. Recombinant human IGF-I (rhIGF-I) was recently shown to decrease serum levels of insulin and C-peptide in fasted normal subjects without affecting plasma glucose levels. In this study we have investigated in six healthy volunteers the responses of glucose, insulin, and C-peptide levels to intravenous rhIGF-I infusions (7 and 14 micrograms/kg.h) during standard oral glucose tolerance tests (oGTT) and meal tolerance tests (MTT), respectively. Glucose tolerance remained unchanged during the rhIGF-I infusions in the face of lowered insulin and C-peptide levels. The decreased insulin/glucose-ratio presumably is caused by an enhanced tissue sensitivity to insulin. The lowered area under the insulin curve during oGTT and MTT as a result of the administration of rhIGF-I were related to the fasting insulin levels during saline infusion (oGTT: r = 0.825, P less than 0.05; MTT: r = 0.895, P less than 0.02). RhIGF-I, however, did not alter the ratio between C-peptide and insulin, suggesting that the metabolic clearance of endogenous insulin remained unchanged. In conclusion, rhIGF-I increased glucose disposal and directly suppressed insulin secretion. RhIGF-I probably increased insulin sensitivity as a result of decreased insulin levels and suppressed growth hormone secretion. RhIGF-I, therefore, may be therapeutically useful in insulin resistance of type 2 diabetes, obesity, and hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding
Defronzo, R. A., Soman, V., Sherwin, R. S., Hendler, R., & Felig, P. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109108 · Cited by 252
RetractedHormone-fuel interrelationships during fasting.
Cahill, G. F., Herrera, M. G., Morgan, A. P., Soeldner, J. S., Steinke, J., Levy, P. L., Reichard, G. A., & Kipnis, D. M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105481 · Cited by 1,036
Henry, R. R., Wallace, P., & Olefsky, J. M. (1986) · Diabetes · doi:10.2337/diab.35.9.990 · Cited by 325
Cited by
Free insulin-like growth factors in human obesity
Frystyk, J., Vestbo, E., Skjærbaek, C., Mogensen, C. E., & Ørskov, H. (1995) · Metabolism · doi:10.1016/0026-0495(95)90219-8 · Cited by 353
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1
LeRoith, D., & Yakar, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0427 · Cited by 344
“Administration of rhIGF1 resulted in a significant improvement in insulin sensitivity and a decrease in blood glucose levels”
BackgroundLiver-Specific igf-1 Gene Deletion Leads to Muscle Insulin Insensitivity
Yakar, S., Liu, J.-L., Fernandez, A. M., Wu, Y., Schally, A. V., Frystyk, J., Chernausek, S. D., Mejia, W., & Le Roith, D. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1110 · Cited by 343
Free insulin‐like growth factors (IGF‐I and IGF‐II) in human serum
Frystyk, J., Skjærbæk, C., Dinesen, B., & Ørskov, H. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00602-4 · Cited by 306
Ren, J., Samson, W. K., & Sowers, J. R. (1999) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1999.1036 · Cited by 304
Insulin-like growth factor-1 deficiency and metabolic syndrome
Aguirre, G. A., De Ita, J. R., de la Garza, R. G., & Castilla-Cortazar, I. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0762-z · Cited by 295
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S. A., Acuña‐Castroviejo, D., Coto‐Montes, A., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 294
Rajpathak, S. N., Gunter, M. J., Wylie‐Rosett, J., Ho, G. Y. F., Kaplan, R. C., Muzumdar, R., Rohan, T. E., & Strickler, H. D. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.919 · Cited by 265
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126434 · Cited by 248
Hartman, M. L., Clayton, P. E., Johnson, M. L., Celniker, A., Perlman, A. J., Alberti, K. G., & Thorner, M. O. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116480 · Cited by 192
Growth hormone, IGF‐I and insulin and their abuse in sport
Holt, R. I. G., & Sönksen, P. H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.99 · Cited by 190
“The effects of an intravenous IGF-I infusion in humans are similar to those described in animals and lead to hypoglycaemia (Zenobi et al., 1992).”
MethodProlonged Sleep Restriction Affects Glucose Metabolism in Healthy Young Men
van Leeuwen, W. M. A., Hublin, C., Sallinen, M., Härmä, M., Hirvonen, A., & Porkka-Heiskanen, T. (2010) · International Journal of Endocrinology · doi:10.1155/2010/108641 · Cited by 102
Succurro, E., Andreozzi, F., Marini, M. A., Lauro, R., Hribal, M. L., Perticone, F., & Sesti, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.011 · Cited by 85
Crossey, P. A., Jones, J. S., & Miell, J. P. (2000) · Diabetes · doi:10.2337/diabetes.49.3.457 · Cited by 72
Metadata
- Authors
- Zenobi, P. D., Graf, S., Ursprung, H., & Froesch, E. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1992-06-01
- Volume
- 89
- Issue
- 6
- Pages
- 1908-1913
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1968300734
- Cited by
- 135
- References
- 3
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.